When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3‐ITD AML-Reference-Cited by-同舟云学术

When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3‐ITD AML

Published:2021-08-06 Issue:11 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Knight Tristan E.¹^ORCID,Ge Yubin²³,Taub Jeffrey W.⁴⁵⁶^ORCID,Hitzler Johann¹⁷^ORCID,Krueger Joerg¹

Affiliation:

1. Division of Hematology/Oncology, Department of Pediatrics The Hospital for Sick Children (SickKids) and the University of Toronto Toronto Ontario Canada

2. Department of Oncology Wayne State University School of Medicine Detroit Michigan USA

3. Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute Wayne State University School of Medicine Detroit Michigan USA

4. Division of Hematology/Oncology Children's Hospital of Michigan Detroit Michigan USA

5. Department of Pediatrics Wayne State University School of Medicine Detroit Michigan USA

6. Department of Pediatrics Central Michigan University Mt. Pleasant Michigan USA

7. Developmental and Stem Cell Biology The Hospital for Sick Children Research Institute Toronto Ontario Canada

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29278

Reference57 articles.

1. A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’

2. The high cost of prescription drugs: causes and solutions

3. Barriers to Medication Access in Pediatric Oncology in the United States

4. Medication prior authorization in pediatric hematology and oncology

5. The Relationship Between Insurance Coverage and Cancer Care: A Literature Synthesis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ensuring access to innovative therapies for children, adolescents, and young adults across Canada: The single patient study experience;Paediatrics & Child Health;2023-04-20

2. “FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors;Cancers;2022-07-13